Literature DB >> 15007574

The role of qualitative and quantitative MRI assessment of multiple sclerosis lesions according to their in evaluating the efficacy of intravenous immunoglobulin G.

B Koçer1, S Yildirim-Gürel, E T Tali, C Irkeç, S Işik.   

Abstract

We evaluation of the role of determining the distribution of brain-stem, cerebellar and cerebral lesions in number and volume by MRI in determining the efficiency of treatment of multiple sclerosis (MS). We studied 24 patients diagnosed as having relapsing and remitting MS, of whom 12 received intravenous immunoglobulin G; a control group of 12 were given placebo. In a double-blind study, MRI was obtained initially and at 3, 6 and 9 months, and interpreted without knowledge of clinical findings, laboratory tests or treatment. The lesions were classified according to their distribution and evaluated qualitatively and quantitatively. Each patient was also examined clinically and scored according to the expanded disability status scale (EDSS) following every MRI examination. All patients in the treatment group showed significant improvement. The lesions decreased in both in size and number in all sites. In the control group lesions increased both in number and size in all sites, but only the increase between 3()and 6 months was statistically significant. In both groups, significant apparent changes were detected in the cerebellum and brain stem. Volumetric evaluation was found to be more helpful than qualitative assessment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15007574     DOI: 10.1007/s00234-003-1088-8

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  15 in total

Review 1.  Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.

Authors:  P D Molyneux; M Filippi; F Barkhof; C Gasperini; T A Yousry; L Truyen; H M Lai; M A Rocca; I F Moseley; D H Miller
Journal:  Ann Neurol       Date:  1998-03       Impact factor: 10.422

2.  Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis. The MS Study Group.

Authors:  G J Zhao; D K Li; J S Wolinsky; R A Koopmans; W Mietlowski; W K Redekop; A Riddehough; K Cover; D W Paty
Journal:  J Neuroimaging       Date:  1997-01       Impact factor: 2.486

3.  Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients.

Authors:  E W Willoughby; E Grochowski; D K Li; J Oger; L F Kastrukoff; D W Paty
Journal:  Ann Neurol       Date:  1989-01       Impact factor: 10.422

4.  Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis.

Authors:  P S Sorensen; B Wanscher; C V Jensen; K Schreiber; M Blinkenberg; M Ravnborg; H Kirsmeier; V A Larsen; M L Lee
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

5.  Magnetic resonance imaging and clinical correlations in multiple sclerosis.

Authors:  S J Huber; G W Paulson; D Chakeres; A Pakalnis; M Brogan; B L Phillips; M A Myers; K W Rammohan
Journal:  J Neurol Sci       Date:  1988-08       Impact factor: 3.181

6.  Intravenous immune globulin in multiple sclerosis: clinical and neuroradiological results and implications for possible mechanisms of action.

Authors:  A Achiron; Y Barak; M Goren; U Gabbay; S Miron; Z Rotstein; S Noy; I Sarova-Pinhas
Journal:  Clin Exp Immunol       Date:  1996-05       Impact factor: 4.330

7.  Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden.

Authors:  S J Khoury; C R Guttmann; E J Orav; M J Hohol; S S Ahn; L Hsu; R Kikinis; G A Mackin; F A Jolesz; H L Weiner
Journal:  Neurology       Date:  1994-11       Impact factor: 9.910

8.  Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study.

Authors:  A F Hahn; C F Bolton; D Zochodne; T E Feasby
Journal:  Brain       Date:  1996-08       Impact factor: 13.501

9.  Quantification of MRI lesion load in multiple sclerosis: a comparison of three computer-assisted techniques.

Authors:  J Grimaud; M Lai; J Thorpe; P Adeleine; L Wang; G J Barker; D L Plummer; P S Tofts; W I McDonald; D H Miller
Journal:  Magn Reson Imaging       Date:  1996       Impact factor: 2.546

10.  Multiple sclerosis: a serial study using MRI in relapsing patients.

Authors:  C Isaac; D K Li; M Genton; C Jardine; E Grochowski; M Palmer; L F Kastrukoff; J Oger; D W Paty
Journal:  Neurology       Date:  1988-10       Impact factor: 9.910

View more
  7 in total

Review 1.  [High-dose intravenous immunoglobulins in the treatment of multiple sclerosis. An update].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2005-10       Impact factor: 1.214

Review 2.  Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis.

Authors:  Ales Dudesek; Uwe K Zettl
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

3.  IVIG trials in MS. Is albumin a placebo?

Authors:  Otto R Hommes; Judith Haas; Per Soelberg-Sorenson; Mieke Friedrichs
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

4.  9 Human Immunoglobulins.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

Review 5.  [Intravenous immunoglobulins in multiple sclerosis. An update].

Authors:  S Schwarz; H-M Meinck; B Storch-Hagenlocher
Journal:  Nervenarzt       Date:  2009-08       Impact factor: 1.214

6.  Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: A meta-analysis.

Authors:  Alireza Olyaeemanesh; Mahbobeh Rahmani; Reza Goudarzi; Abulghasem Rahimdel
Journal:  Med J Islam Repub Iran       Date:  2016-02-23

7.  Effectiveness and tolerability of different therapies in preventive treatment of MOG-IgG-associated disorder: A network meta-analysis.

Authors:  Xiaofei Wang; Lingyao Kong; Zhengyang Zhao; Ziyan Shi; Hongxi Chen; Yanlin Lang; Xue Lin; Qin Du; Hongyu Zhou
Journal:  Front Immunol       Date:  2022-07-26       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.